Faron Pharmaceuticals OY (FARN) NPV
2.50p
(1.41%)
- Add to watchlist
- Create an alert
- This stock can be held in a
2.50p
(1.41%)
Deal for just £11.95 per trade in a
Stocks and Shares ISA,
Lifetime ISA
,
SIPP
or
Fund and Share Account
2.50p
(1.41%)
Deal for just £11.95 per trade in a
Stocks and Shares ISA,
Lifetime ISA
,
SIPP
or
Fund and Share Account
Share news, reports & tips
-
Faron issuing second tranche of unsecured convertible bonds
11 December 2025 16:32
(Sharecast News) - Faron Pharmaceuticals said on Thursday that its board had approved the issue of the second tranche of its amortising senior unsecured convertible bonds to an entity managed by Heights...
-
Faron Pharmaceuticals appoints new finance chief
1 December 2025 11:48
(Sharecast News) - Faron Pharmaceuticals announced the appointment of Jurriaan Dekkers as its chief financial officer on Monday, strengthening its senior leadership team as the clinical-stage biotech...
-
Faron strengthens bexmarilimab potential with fresh trial data
20 October 2025 10:04
(Sharecast News) - Faron Pharmaceuticals said on Monday that updated results from its phase one and two 'BEXMAB' study showed further improvement in the clinical performance of bexmarilimab,...
-
Faron narrows first-half losses as it advances its lead asset
27 August 2025 08:56
(Sharecast News) - Faron Pharmaceuticals reported a series of first-half clinical and financial milestones on Wednesday, as it advanced its lead asset, bexmarilimab, through late-stage development in...
-
Faron secures FDA pathway for lead cancer therapy
18 August 2025 11:44
(Sharecast News) - Faron Pharmaceuticals said on Monday that it has secured a clear regulatory pathway for the potential approval of its lead cancer therapy bexmarilimab, following positive feedback from the...
-
Faron Pharmaceuticals appoints chief business officer
21 May 2025 14:31
(Sharecast News) - Faron Pharmaceuticals announced the appointment of Ralph Hughes as its chief business officer on Wednesday, effective 28 May, as the clinical-stage biopharma firm sharpened its focus on...
-
Faron enters financing arrangement with Heights Capital Management entity
3 April 2025 10:28
(Sharecast News) - Faron Pharmaceuticals announced on Thursday that it has entered into a financing arrangement with an entity managed by Heights Capital Management for up to €35m in convertible bonds,...
-
Faron identifies final patient in BEXMAB phase two study
31 January 2025 11:29
(Sharecast News) - Faron Pharmaceuticals announced on Friday that it has identified the final patient for its BEXMAB phase two dose optimisation study in refractory or relapsed myelodysplastic syndrome (r/r...
-
Faron Pharmaceuticals reports regulatory progress in the UK
2 December 2024 11:50
(Sharecast News) - Clinical-stage biopharmaceutical company Faron Pharmaceuticals announced significant regulatory progress in the UK for its lead asset bexmarilimab on Monday.
-
Faron announces promising MDS trial results
27 November 2024 11:39
(Sharecast News) - Faron Pharmaceuticals announced promising interim phase two results from its 'BEXMAB' trial on Wednesday, targeting relapsed or refractory myelodysplastic syndrome (r/r MDS)...
-
Faron Pharmaceuticals files new patent for Clever-1
11 November 2024 13:52
(Sharecast News) - Faron Pharmaceuticals, a clinical-stage biopharmaceutical company specialising in immunotherapies for cancer and inflammatory diseases, announced the filing of a new patent application for...
-
Faron Pharmaceuticals candidate gets FDA fast track designation
27 August 2024 13:00
(Sharecast News) - Clinical-stage biopharmaceutical company Faron Pharmaceuticals announced on Tuesday that its lead candidate, bexmarilimab, has been granted fast track designation by the US Food and Drug...
Company announcements Announcements
-
Faron issues second tranche of bonds with an aggregated principal amount of EUR 10 million under its convertible bond arrangemen
11 December 2025 08:30
Faron Pharmaceuticals Oy (DI)
-
Faron Pharmaceuticals Ltd: Holding(s) in Company
4 December 2025 16:00
Faron Pharmaceuticals Oy (DI)
-
Faron Pharmaceuticals Ltd: Registration of New Shares
3 December 2025 10:00
Faron Pharmaceuticals Oy (DI)
-
Faron Pharmaceuticals Ltd: Approval of Share Subscriptions Based on Special Rights in connection with Amortisation of the First
3 December 2025 07:00
Faron Pharmaceuticals Oy (DI)
-
Faron Pharmaceuticals Ltd: Grant of Options
2 December 2025 07:00
Faron Pharmaceuticals Oy (DI)
-
Faron Pharmaceuticals Ltd: Appointment of CFO
1 December 2025 07:00
Faron Pharmaceuticals Oy (DI)
-
Faron's Financial Calendar for 2026
27 November 2025 07:00
Faron Pharmaceuticals Oy (DI)
-
Updated BEXMAB Phase I/II Data presented at ESMO 2025 shows further improvement, strengthening the clinical profile of bexmarili
20 October 2025 06:00
Faron Pharmaceuticals Oy (DI)
-
Faron Pharmaceuticals Ltd: Registration of New Shares
3 October 2025 10:00
Faron Pharmaceuticals Oy (DI)
-
Faron Pharmaceuticals Ltd: Approval of Share Subscriptions Based on Special Rights in connection with Amortisation of the First
3 October 2025 06:00
Faron Pharmaceuticals Oy (DI)
-
Faron Pharmaceuticals Ltd: Exercise of Options, Director Dealing and Issue of Equity
19 September 2025 06:00
Faron Pharmaceuticals Oy (DI)
-
Correction: FARON PHARMACEUTICALS LTD: HALF-YEAR FINANCIAL RESULTS 1 JANUARY - 30 JUNE 2025
12 September 2025 15:25
Faron Pharmaceuticals Oy (DI)
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. This news service is operated by Digital Look Ltd. Republication or redistribution of Digital Look Ltd content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Digital Look Ltd. Please see https://www.sharecast.com/newsfeedterms/index.html for our terms and conditions.
© Digital Look Ltd 1998-2025. All rights reserved.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.